Bank of New York Mellon Corp Has $9.32 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Bank of New York Mellon Corp lowered its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 989,452 shares of the biopharmaceutical company’s stock after selling 25,876 shares during the period. Bank of New York Mellon Corp owned about 0.33% of Amicus Therapeutics worth $9,321,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. HealthInvest Partners AB lifted its stake in shares of Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after purchasing an additional 51,368 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. Tempus Wealth Planning LLC acquired a new stake in shares of Amicus Therapeutics in the 4th quarter valued at $259,000. Neo Ivy Capital Management acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at $702,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Amicus Therapeutics by 51.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock valued at $2,381,000 after purchasing an additional 75,807 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on FOLD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $8.90 on Friday. The stock has a market cap of $2.73 billion, a P/E ratio of -49.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The stock’s 50-day moving average is $9.39 and its 200-day moving average is $10.18. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.